- Report
- March 2022
- 77 Pages
Global
From €3500EUR$4,109USD£3,078GBP
- Report
- September 2022
- 269 Pages
Global
From €1825EUR$2,000USD£1,551GBP
- Report
- September 2022
- 80 Pages
Africa
From €1825EUR$2,000USD£1,551GBP
- Report
- January 2025
- 132 Pages
Global
From €867EUR$950USD£737GBP
- Report
- December 2023
- 132 Pages
Global
From €867EUR$950USD£737GBP
- Report
- November 2021
- 600 Pages
Global
From €3650EUR$4,000USD£3,101GBP
The Migraine Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Migraine drugs are used to treat the symptoms of migraine headaches, such as nausea, vomiting, and sensitivity to light and sound. These drugs can be divided into two categories: abortive and preventive. Abortive drugs are taken at the onset of a migraine attack to reduce the severity of symptoms, while preventive drugs are taken on a regular basis to reduce the frequency of migraine attacks. Common abortive drugs include triptans, ergot alkaloids, and non-steroidal anti-inflammatory drugs (NSAIDs). Common preventive drugs include beta-blockers, anticonvulsants, and serotonin receptor agonists.
Some companies in the Migraine Drug market include GlaxoSmithKline, Pfizer, Novartis, Merck, and Allergan. Show Less Read more
